XT
PRQR icon

XTX Topco’s ProQR Therapeutics PRQR Stock Holding History

XTX Topco’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-77,287
Closed -$125K – 4591
2026
Q1 		$125K Sell
77,287
-40,613
-34% -$66.6K ﹤0.01% 3023
2025
Q4 		$238K Buy
117,900
+107,713
+1,057% +$252K 0.01% 2266
2025
Q3 		$21.7K Buy
+10,187
New +$22.3K ﹤0.01% 2316
2025
Q2 		– Sell
-16,079
Closed -$21.4K – 2999
2025
Q1 		$21.4K Sell
16,079
-45,518
-74% -$96.9K ﹤0.01% 2128
2024
Q4 		$163K Buy
+61,597
New +$196K 0.01% 1632
2023
Q3 		– Sell
-16,405
Closed -$26.6K – 1923
2023
Q2 		$26.6K Buy
16,405
+6,245
+61% +$12.2K ﹤0.01% 1298
2023
Q1 		$21.6K Buy
+10,160
New +$31.1K ﹤0.01% 1209
2022
Q2 		– Sell
-210,587
Closed -$191K – 1060
2022
Q1 		$191K Buy
+210,587
New +$705K 0.08% 427

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

XTX Topco's PRQR Position: Q2 2026 in Review

XTX Topco sold out of ProQR Therapeutics (PRQR) in Q2 2026, closing a stake of 77,287 shares — an estimated $125K sold.

XTX Topco first reported a position in PRQR in Q1 2022 and held it in 8 quarters. The position peaked at $238K in Q4 2025. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • XTX Topco reported no remaining ProQR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 77,287 ProQR Therapeutics shares in Q2 2026, an estimated $125K.
  • XTX Topco first reported a position in ProQR Therapeutics in Q1 2022 and held it in 8 quarters.
  • XTX Topco's ProQR Therapeutics position peaked at $238K in Q4 2025.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.